India’s health minister said on Monday that the country would resume exports of Covid-19 vaccines, five months after halting shipments during its own devastating wave of infections.
The health minister, Mansukh Mandaviya, said that exports would resume starting next month, and that the vaccines would help fulfill India’s commitment to Covax, the United Nations-backed vaccine sharing initiative.
He said that India would produce more than 300 million vaccine doses in October and a total of at least a billion over the final three months of 2021.
“We will help the world and also fulfill our commitment toward Covax,” Mr. Mandaviya said.
The minister did not specify which vaccines India would supply to Covax, or how many doses. Before halting exports in April, the country exported 66.4 million doses, a combination of commercial sales, grants and shipments to Covax, which is designed mainly to help low- and middle- income countries.
India’s decision comes as its domestic vaccination campaign has picked up after a slow start. The government says it expects to finish inoculating all 944 million adults in the country by December.
So far, 61 percent of adults in India have received their first dose, according to government data. The two main vaccines in use are Covishield, the local name for the AstraZeneca vaccine, manufactured in India by the Serum Institute of India, and Covaxin, produced by the Indian company Bharat Biotech.